Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Short term Debt (2021 - 2024)

Historic Short term Debt for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $32.8 million.

  • Abivax's Short term Debt changed N/A to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year change of. This contributed to the annual value of $13.9 million for FY2024, which is 6555.37% down from last year.
  • Abivax's Short term Debt amounted to $32.8 million in Q3 2025.
  • Over the past 5 years, Abivax's Short term Debt peaked at $40.2 million during Q4 2023, and registered a low of $2.7 million during Q2 2024.
  • In the last 5 years, Abivax's Short term Debt had a median value of $15.4 million in 2025 and averaged $20.9 million.
  • Its Short term Debt has fluctuated over the past 5 years, first tumbled by 6536.87% in 2024, then surged by 49910.74% in 2025.
  • Abivax's Short term Debt (Quarter) stood at $13.0 million in 2021, then surged by 163.78% to $34.2 million in 2022, then increased by 17.38% to $40.2 million in 2023, then crashed by 65.37% to $13.9 million in 2024, then surged by 136.05% to $32.8 million in 2025.
  • Its Short term Debt stands at $32.8 million for Q3 2025, versus $16.0 million for Q2 2025 and $14.7 million for Q1 2025.